Search

Corvus Pharmaceuticals Inc

Закрыт

10.01 -2.25

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

9.78

Макс.

10.05

Ключевые показатели

By Trading Economics

Доход

-4.3M

-18M

Прибыль на акцию

-0.19

Сотрудники

37

EBITDA

-5.3M

-17M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+186.64% upside

Дивиденды

By Acuity

Следующий отчет о доходах

5 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-245M

879M

Предыдущая цена открытия

12.26

Предыдущая цена закрытия

10.01

Corvus Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

31 окт. 2026 г., 23:51 UTC

South Korea's October 2026 Exports YoY data set for release, with market expecting a growth rate of 0.932% amid strong previous performance and positive economic outlooks.

31 окт. 2026 г., 23:31 UTC

Australia's Balance of Trade data set for November 5, with expectations of a AUD 1 billion surplus amid cautious optimism in local markets despite global economic pressures.

31 окт. 2026 г., 23:31 UTC

Brazil's Industrial Production Data Release on November 5, 2026, Sparks Caution Amid Recent Declines and Market Volatility.

31 окт. 2026 г., 23:12 UTC

Bank of England's MPC Meeting on November 5 Expected to Announce 25 Basis Point Rate Hike Amid Persistent Inflation and Economic Growth.

31 окт. 2026 г., 23:11 UTC

Macro News

The DAX 30 Index declined in after-market hours amid broader market pressures from disappointing earnings and rising oil prices, contributing to increased volatility.

31 окт. 2026 г., 23:01 UTC

Macro News

Ethereum is advancing amid broader market volatility following a major hack on Binance, which resulted in the theft of approximately $6.36 billion.

31 окт. 2026 г., 23:01 UTC

Macro News

Bitcoin prices are rising as large investors buy in after a significant hack on Binance that moved $6.36 billion from its wallets.

31 окт. 2026 г., 22:51 UTC

Mexico's Consumer Confidence Index set for release on November 4, with analysts predicting continued pessimism amid declining sentiment and external economic pressures.

31 окт. 2026 г., 22:31 UTC

Australia's Building Permits MoM Preliminary data for September 2026 set to release on November 2, with a forecasted modest increase of 2.1% amid concerns over housing sector weakness and rising borrowing costs.

31 окт. 2026 г., 22:31 UTC

Cautious Optimism for South Korea's S&P Global Manufacturing PMI Release Amid Strong Domestic Data and Global Economic Concerns

31 окт. 2026 г., 22:31 UTC

Mexico's Business Confidence data release on November 3 follows a stronger-than-expected Q3 GDP growth of 3.2%, raising hopes for improved sentiment among business executives.

31 окт. 2026 г., 22:31 UTC

Brazil's Central Bank to Release Key Insights on SELIC Rate Amid High-Interest Concerns and Global Monetary Policy Tightening, November 3, 2026.

31 окт. 2026 г., 22:31 UTC

Macro News

The S&P 500 Index is trading modestly higher in after-market hours, amid governance concerns following the detention of Borsa Istanbul's CEO over bribery allegations.

31 окт. 2026 г., 22:31 UTC

Macro News

The Nasdaq 100 Index is trading modestly higher in after-market hours amid broader market pressures from a significant hack on Binance and concerns over AI commitments.

31 окт. 2026 г., 22:21 UTC

Mortgage Rates Show Slight Easing Ahead of MBA Release, Offering Hope to Homebuyers Amid Economic Uncertainties

31 окт. 2026 г., 22:01 UTC

Australia's Ai Group Industry Index set for November 3 release, with analysts predicting continued industrial decline amid global tech sector volatility.

31 окт. 2026 г., 22:01 UTC

Turkey's Trade Balance Prel Release on November 4, 2026: Market Cautiously Awaits Potential Improvement Amid Economic Confidence Decline and Ongoing Import Challenges.

31 окт. 2026 г., 21:51 UTC

Italy's Retail Sales Expected to Rise 0.2% Amid Rising Inflation and Stagnant GDP Concerns

31 окт. 2026 г., 21:51 UTC

Euro Area Retail Sales Expected to Decline 0.1% Amidst Mixed Economic Sentiment and Rising Inflation Concerns

31 окт. 2026 г., 21:51 UTC

France's Trade Deficit Expected at €5.8 Billion Amidst Economic Contraction and Rising Inflation Concerns

31 окт. 2026 г., 21:51 UTC

France's Industrial Production Expected to Rise 0.4% Amid Mixed Economic Signals and Rising Costs

31 окт. 2026 г., 21:41 UTC

Italy's S&P Global Services PMI set for November 4, with a forecast of 51.0 amid mixed economic signals and rising inflation concerns.

31 окт. 2026 г., 21:31 UTC

Spain's Consumer Confidence Index set for November 3, with analysts predicting stability amid inflation at 4.9% and political uncertainty ahead of snap elections.

31 окт. 2026 г., 21:31 UTC

South Korea's October 2026 Inflation Rate Release Expected at 2.9% Amid Mixed Global Economic Sentiment

31 окт. 2026 г., 21:31 UTC

Switzerland's October 2026 unemployment rate release on November 5 sparks cautious investor sentiment amid economic fluctuations and potential volatility.

31 окт. 2026 г., 21:01 UTC

Euro Area Inflation Rate Flash Report on November 4 Expected Amid Rising Pressures in France and Italy

31 окт. 2026 г., 21:01 UTC

Euro Area's Core Inflation Rate Flash Set for November 4 Amid Rising Inflation Pressures in Major Economies.

31 окт. 2026 г., 21:01 UTC

Euro Area Inflation Rate Expected to Rise to 3.9% in October, Heightening Scrutiny on ECB's Monetary Policy Decisions

31 окт. 2026 г., 21:01 UTC

Correlated Moves
Macro News

Oil (Brent) is lower after Friday's close amid geopolitical concerns, including Russia's diesel export ban and a fire on an oil tanker in the Strait of Hormuz.

31 окт. 2026 г., 20:51 UTC

Macro News

The U.S. Dollar Index is roughly flat in after-market hours, as major firms raised off-balance sheet AI commitments from $3 trillion to about $4.1 trillion.

Сравнение c конкурентами

Изменение цены

Corvus Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

186.64% рост

Прогноз на 12 месяцев

Средняя 28.75 USD  186.64%

Максимум 33 USD

Минимум 27 USD

Основано на мнении 4 аналитиков Wall Street, спрогнозировавших целевые цены для Corvus Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

4 ratings

4

Покупка

0

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat